

September 8, 2021



Moleculin to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

HOUSTON, Sept. 8, 2021 /PRNewswire/ --**Moleculin Biotech, Inc.**, (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that [Walter Klemp, President and Chief Executive Officer](#) of Moleculin, will present at the virtual [H.C. Wainwright 23rd Annual Global Investment](#) Conference taking place September 13-15, 2021.



In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the [conference website](#).

A [video webcast](#) of the presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM ET for those registered for the event and will be accessible on the [Events](#) page in the [Investors](#) section of the Company's website (www.moleculin.com). The webcast replay will be archived for 90 days following the event.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to be noncardiotoxic and to avoid multidrug resistance mechanisms. In addition, Annamycin has been shown in animal models to reach higher concentration levels than doxorubicin (a leading anthracycline) in certain key organs, such as the lungs, liver and pancreas considered to be difficult-to-reach "sanctuary sites" for tumors. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.


Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other

cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit www.moleculin.com and connect on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com

 View original content to download multimedia <https://www.prnewswire.com/news-releases/moleculin-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301370713.html>

SOURCE Moleculin Biotech, Inc.